Unusual 11 Mid-Day Movers 6/26: NCS, PALM, SCON, AMLN Higher; DWRI, GRB, BLUD, RBN Lower

June 26, 2009 12:39 PM EDT

Design Within Reach, Inc. (Nasdaq: DWRI) 40.6% LOWER; has notified the NASDAQ Stock Market of its intent to delist its common stock from the NASDAQ Global Market. The Company currently anticipates that on July 6, 2009 it will file with the Securities and Exchange Commission and NASDAQ a Form 25 relating to the delisting of its common stock.

NCI Building Systems (NYSE: NCS) 19% HIGHER; seeing some follow-through upside today after yesterday's 22% run-up. Prior to yesterday's move higher, shares of NCI have only had 3 closes in positive territory since reporting its Q2 results on June 9.

Palm, Inc. (Nasdaq: PALM) 15.8% HIGHER; reports Q4 adj-loss of $0.40, versus the analyst estimate of ($0.62). Revenue for the quarter was $113.2 million, versus the consensus of $80.64 million.

Superconductor Technologies (Nasdaq: SCON) 15.2% HIGHER; jumping today following the disclosure, last night, of a large purchase by Kopp Investment Advisors. As part of a direct offering, Kopp boosted its stake in SCON from 13.7% to 24.8%. Of the 3.7 million share offering, Kopp purchased 3 million shares.

Gerber Scientific, Inc. (NYSE: GRB) 15.1% LOWER; reports Q1 EPS of $0., cents better than the analyst estimate of $0.01. Revenue for the quarter was $ million, versus the consensus of $118.70 million.

Immucor, Inc., (Nasdaq: BLUD) 14.5% LOWER; announced that yesterday the FDA, in an administrative action based on an early January 2009 inspection, issued a notice of intent to revoke the Company's biologics license with respect to its Reagent Red Blood Cells and Anti-E (Monoclonal) Blood Grouping Reagent product. The FDA has not ordered the recall of any of the Company's products. Click here for the full report.

Robbins & Myers (NYSE: RBN) 10.4% LOWER; reports Q3 EPS of $0.31, including a $0.05 benefit from finalizing earlier tax positions, versus the analyst estimate of $0.25. Revenue for the quarter was $143.4 million, versus the consensus of $135.23 million. Sees Q4 EPS of $0.14-$0.24, versus the consensus of $0.26. Robbins & Myers narrowed its FY09 EPS guidance from $1.35-$1.65 to $1.41-$1.51, which compares to the Street estimate of $1.46.

Amylin (Nasdaq: AMLN) 9.6% HIGHER; spiking today as Sanofi-Aventis (NYSE: SNY) is receiving some heat for its diabetes drug, Lantus, a direct competitor to Amylin's Byetta. Analysts at both Morgan Stanley and JPMorgan downgraded the stock. According to U.K. studies, Lantus could offer an increased risk of cancer.

TIBCO Software (Nasdaq: TIBX) 9.6% HIGHER; reports Q2 non-GAAP EPS of $0.11, 2 cents better than the analyst estimate of $0.09. Revenue for the quarter was $142.7 million, versus the consensus of $139.35 million.

Ameron (NYSE: AMN) 9.4% HIGHER; continuing higher today following yesterday's 12.7% run-up on Q2 earnings.

KB Home (NYSE: KBH) 8.7% LOWER; reports Q2 EPS of $(1.03) versus the analyst estimate of ($0.64) Revenue for the quarter was $384.5 million, versus the consensus of $339.13 million. In the current quarter, KB Home said cancellation rate improved to 20% from 28%.

To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.

Related Categories

Special Reports

Stocks Mentioned

Related Entities

• JPMorgan
• Morgan Stanley
• Unusual 11 Mid-Day Movers

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?